Oncology · CAR T-cell TherapyTrial Updateclinicalmid-term

Phase 2 Trial of Lisocabtagene Maraleucel Targets Minimal Residual Disease in Large B-cell Lymphoma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:05:14 AM

Assessment confidence: 74% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 2 trial of lisocabtagene maraleucel represents a significant advancement in CAR T-cell therapy for large B-cell lymphoma, particularly in patients with minimal residual disease. Success in this trial could enhance the competitive landscape for CAR T therapies and establish new treatment paradigms in oncology. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 25 ranked evidence items (16 high-relevance).

Strategic Assessment

Success in this trial may expand the use of CAR T-cell therapies in earlier treatment settings, influencing competitive positioning against other therapies targeting similar patient populations. The strongest clinical anchor is Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (ClinicalTrials.gov), entity match (m d anderson cancer center). In Oncology · CAR T-cell Therapy, 5 regulatory and 6 competitive items passed relevance filtering for M.D.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel).

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Positive trial outcomes may influence regulatory pathways and approvals for CAR T therapies in earlier treatment settings, impacting compliance and market access strategies.

Key Risks

Elevated medium regulatory exposure for M.D. Anderson Cancer Center could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this trial could lead to increased market share for lisocabtagene maraleucel, positioning it favorably against other therapies targeting similar patient populations and potentially driving revenue growth.
Upside for M.D. Anderson Cancer Center may improve if Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for M.D. Anderson Cancer Center may improve if Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (ClinicalTrials.gov) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes, as well as potential regulatory implications.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
ClinicalTrials.govhigh relevance
Entity match (large b-cell lymphoma)
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govhigh relevance
Entity match (m d anderson cancer center)
FDA document
View source
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated Significant Improvement in Minimal Residual Disease Negativity Rat
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase I/II Trial of Lentiviral Gene Transfer for XSCID in Children Over Two Years
Humanexa Signalsmedium relevance
Moderate corpus alignment

Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedhigh relevance
Entity match (large b-cell lymphoma)
FDA document
View source
Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation.
PubMedhigh relevance
Entity match (large b-cell lymphoma)
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

M.D. Anderson Cancer Center
large B-cell lymphoma

Commercial impact

medium

If successful, this trial could lead to increased market share for lisocabtagene maraleucel, positioning it favorably against other therapies targeting similar patient populations and potentially driving revenue growth.

Regulatory impact

medium

Positive trial outcomes may influence regulatory pathways and approvals for CAR T therapies in earlier treatment settings, impacting compliance and market access strategies.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes, as well as potential regulatory implications.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.